Navigation Links
Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
Date:3/31/2009

IRVINE, Calif., March 31 /PRNewswire-FirstCall/ --Cardiogenesis Corporation (Pink Sheets: CGCP) the "Company", a leading developer of surgical products used in the treatment of patients suffering from severe angina, today reported financial results for its fourth quarter and fiscal year ended December 31, 2008.

Fourth Quarter and Fiscal Year 2008 Financial Results

Net revenues in the fourth quarter of 2008 totaled $2,431,000, a 12% decrease from the prior year fourth quarter net revenues of $2,767,000. During the fourth quarter of 2008, the Company sold two lasers and 463 handpiece units as compared to three lasers and 462 handpieces during the fourth quarter of 2007. The lower revenue in the current year quarter is primarily attributable to the decrease in sales of our laser product.

Net revenues for the year ended December 31, 2008 totaled $12,150,000, an increase of approximately 1% from the $12,059,000 of net revenues for the year ended December 31, 2007. The increase in net revenues was due to an increase in laser revenue of $388,000 which was partially offset by decreases in handpiece revenue of $284,000 and service and other revenues of $13,000. During the year ended December 31, 2008 the Company sold 13 lasers and 2,063 handpieces as compared to 14 lasers and 2,293 handpieces in the prior year period.

Richard Lanigan, Cardiogenesis President, stated, "During 2008 we have added essential sales and marketing resources to continue supporting TMR as an adjunctive therapy while implementing new initiatives to gain further adoption of TMR as a 'stand alone' therapy. At the same time we have renewed our efforts on the product development front while generating positive cash flow for the year. We continue to experience excellent gross margins and believe we are well positioned for sales growth going forward."

The Company reported a fourth quarter 2008 operating loss of
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Cardiogenesis Receives FDA Approval for PEARL 5.0 Robotic Hand Piece
2. Cardiogenesis Corporation to Report 2007 Fourth Quarter and Year-End Results on March 4th
3. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
4. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
5. Cardiogenesis Corporation to Report 2008 First Quarter Results on May 15th
6. Cardiogenesis Reports First Quarter 2008 Results
7. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
8. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
9. Cardiogenesis Corporation to Report Third Quarter 2008 Results on November 13th
10. Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
11. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... CA (PRWEB) July 28, 2014 With ... us, it is welcome news that a fire ... than current protection is under development by SunSeeker Enterprises, ... NASA to protect spacecraft from the extreme heat of ... to both firefighters and homes. , “Our firefighters routinely ...
(Date:7/28/2014)... 2014 The report “Industrial Enzymes ... & Beverages, Cleaning Agents, Bio-Fuel, Animal Feed), & ... defines and segments the global industrial enzymes market ... for industrial enzymes. It also identifies driving and ... with analysis of trends, opportunities, burning issues, winning ...
(Date:7/28/2014)... from The University of Texas Health Science Center at San ... a combination of pills that cures 9 of 10 hepatitis ... simeprevir, with or without ribavirin, cured 93 percent of patients ... to the study published today in The Lancet . ... , Eric Lawitz, M.D., clinical professor in the School of ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Recent research ... desk all day for years can lead to a ... cardiovascular disease. But using a standing desk, or an ... pain, often driving office workers back to a seated ... are designed to alleviate this leg pain and ...
(Date:7/28/2014)... MONDAY, July 28, 2014 (HealthDay News) -- A ... stiffness in older people may increase the risk ... suggests. A British study found that patients ... vascular disease -- conditions that affect the blood ... factors of patients with polymyalgia rheumatica to reduce ...
Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:New Standing Desk Anti-fatigue Mats from Martinson-Nicholls Reduce Leg Fatigue and Discomfort Working at Standing and Sit-to-Stand Desks 2Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2
... dating has not only shed its stigma, it has ... other than meeting through friends, according to a new ... The digital revolution in romance is a boon ... potential partners, reports the team of psychological scientists who ...
... , FRIDAY, Feb. 3 (HealthDay News) -- ,Extended synaptic development ... new study suggests. During the first few years of ... information and experiences from the environment in a way that ... This is due to extended synaptic development, according to the ...
... been mapped with unprecedented accuracy in the bloodstream of ... brand new approach, in an attempt to assess and ... through the body, and solve the problem of predicting ... to a previous generation of systems, the researchers state ...
... aged 70 and over will increase by 40% in ... over will more than double1. Health authorities and the ... of people suffering costly and debilitating age-related chronic diseases ... dementia. The significant increase in the numbers of people ...
... (February 1, 2012) Rates of diabetes vary widely across ... by Dr. Longjian Liu of Drexel University,s School of ... diabetes now live in developing countries. Liu,s study found ... in developing countries, and that one in 10 diagnosed ...
... , THURSDAY, Feb. 2 (HealthDay News) -- Sometimes, there,s nothing ... that where the itch resides is key to ... understanding of itch and might even help folks battling itchy ... professor of dermatology at Wake Forest Baptist Medical Center in ...
Cached Medicine News:Health News:Online dating research shows cupid's arrow is turning digital 2Health News:Online dating research shows cupid's arrow is turning digital 3Health News:Why Human Brains Are Smarter Than Chimp Brains 2Health News:New technology to tackle treatment-resistant cancers 2Health News:New study to assess 3 simple, cost-effective strategies to promote healthy aging 2Health News:Diabetes rates vary widely in developing countries, 1 in 10 cases untreated 2Health News:Pleasure in Scratching an Itch May Depend on Location 2
(Date:7/28/2014)... 28, 2014  VigeneTech, Inc, in collaboration with ... Data Analysis Software, an OEM software solution for ... develops and offers varieties of bead-based multi-analyte immunoassay ... support of VigeneTech,s data analysis software, FCS data ... easily reported LEGENDplex™ software is ...
(Date:7/28/2014)... 2014 Research and Markets  has announced the ... report to their offering. ... leads to inflammation and pain in the human body,s joints ... it causes inflammation of the tissues that surround the joints ... of RA begin slowly, usually just mild pain around the ...
(Date:7/28/2014)... , July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... company, announced today that its new PicoWay® device has ... types and colors and pigmented lesions on any skin ... device, with 532nm and 1064nm wavelengths, which utilizes Syneron,s ... using pulses which are trillionths of a second, known ...
Breaking Medicine Technology:VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4
... and Only Approved Platelet Producer in Europe Represents ... Switzerland, Feb. 6 Amgen (Nasdaq: ... (EC) has granted marketing authorisation for Nplate(R) (romiplostim) ... (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory ...
... CAMBRIDGE, Mass. and LONDON, Feb. 6 Idenix Pharmaceuticals, ... today announced the execution of a license agreement granting ... a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase ... treatment of HIV/AIDS. New NNRTIs are needed to ...
Cached Medicine Technology:Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 2Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 3Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 4Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 5
... cervical stabilization from neutral to ... widening under occiput when collar ... fasterner.,Exo-Static™ Collar with Chin Piece ... neutral position and restricts lateral ...
... Padding&trade is perfect for use for lightweight ... materials or used to line braces, prosthetics, ... against shock and vibration and conforms to ... and chaffing. It is a 2mm thick ...
... support and stabilization for muscles and ligaments ... pain and discomfort. Strong elastic abdominal ... for varying degrees of compression. Two ... for extra-firm support. Tapered in front ...
... Designed with patient need and comfort ... Appliance) family of products effectively address ... The Chairback frame attachment provides optimal ... (LSO) provides superior support for patient ...
Medicine Products: